Response to 'The effect of PD-L1 testing on the cost-effectiveness of immune checkpoint inhibitors' Dear Editor, I am writing to highlight several inaccuracies in calculation of costs in a recent publication by Aguiar et al. [1] which assesses the effect of PD-L1 testing on the cost-effectiveness of immune checkpoint inhibitors in 2 l NSCLC.
Dear Editor, I am writing to highlight several inaccuracies in calculation of costs in a recent publication by Aguiar et al. [1] which assesses the effect of PD-L1 testing on the cost-effectiveness of immune checkpoint inhibitors in 2 l NSCLC.
As of November 2016, the date authors refer to for obtaining atezolizumab costs, the correct wholesale acquisition cost (WAC) for atezolizomab was $8620 for a 1200 mg vial. This translates to a price of $7.183/mg for atezolizumab. Aguiar et al. assumed a price of $10.42/mg, which is incorrect. The source for this cost is not stated in the manuscript.
While the date for obtaining atezolizumab costs was November 2016, the authors used February 2016 costs for the other two agents. As of November 2016, the WAC for nivolumab and pembrolizumab was $25.07/mg and $44.46/mg, respectively, which is higher than the assumption of $24.69/mg and $43.80/ mg made in the Aguiar et al. manuscript.
The authors state that they conducted analyses from US Medicare perspective. The CMS payment limit for atezolizumab was unavailable in 2016 and hence the WAC ($7.183/mg) could be used. The CMS payment limit in November 2016 was $26.064/ mg for nivolumab and $46.495/mg for pembrolizumab; both higher than the assumptions in the manuscript.
Thus, the manuscript overestimates the cost of atezolizumab, while simultaneously underestimating the cost of the other two agents.
In November 2016, nivolumab and pembrolizumab had a flat dose as per the US package insert. Pembrolizumab had a flat dose of 200 mg Q3W and nivolumab 240 mg Q2W. Aguiar et al. do not state the dose assumptions for pembrolizumab and nivolumab. Based on Table 2 , it appears that they assumed weight based dosing for these two drugs. At the assumed weight of 70 kg, the total dose for pembrolizumab (2 mg/kg) is 140 mg; much lower than the label flat dose of 200 mg. The assumed total dose for nivolumab (3 mg/kg) is only 210 mg, which is lower than the label flat dose of 240 mg. Thus, the manuscript does not align with the US label and underestimates the cost of these drugs. 
